Navigation Links
Champions' CFO Resigns
Date:1/14/2011

BALTIMORE, Jan. 14, 2011 /PRNewswire/ -- Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company with a predictive translational platform aimed at accelerating the development and enhancing the value of oncology drugs, announced today the resignation of Mark Schonau, Champions' Chief Financial Officer. Mr. Schonau indicated that he has no disagreements with management and has resigned to pursue other opportunities. Champions is seeking chief financial officer candidates and intends to complete the search in the near future.

About Champions Biotechnology, Inc.

Champions Biotechnology, Inc. is engaged in the development of advanced translational platforms and tumor specific data to enhance and accelerate the value of oncology drugs. The Company's Technology Platform is a novel approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments (Champions Tumorgrafts(TM)) in a manner that preserves the biological characteristics of the original human tumor. Early studies suggest that unlike traditional xenografts, these Tumorgrafts closely reflect human cancer biology and their response to drugs is predictive of clinical outcomes in cancer patients. Champions Biotechnology leverages its preclinical platform to evaluate drug candidates and to develop a portfolio of novel therapeutic candidates. As drugs progress through early stage development, the Company plans to sell, partner or license them to pharmaceutical and/or biotechnology companies, as appropriate. The Company also offers its predictive preclinical platform and tumor specific data to physicians for personalized patient care and to companies for evaluation of oncology drugs in models that integrate prognostic testing with biomarker discovery.

www.championsbiotechnol
'/>"/>

SOURCE Champions Biotechnology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Champions Biotechnology Awarded $1.46 million in Grants
2. Champions Biotechnology Announces Agreement With Cephalon for the Evaluation of a Novel Oncology Compound Using Predictive Biomerk Tumorgraft™ Platform
3. Higher Education Leaders Receive TCWF Champions of Health Professions Diversity Award
4. Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results
5. Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
6. U.S. Patent Issued for Champions Biotechnologys Lead Oncology Drug
7. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
8. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
9. John A. MacPhee Resigns From Strativa Pharmaceuticals
10. Paul D. Duke Resigns From Mesas Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... 2013  Omnicell, Inc. (NASDAQ: OMCL ... management solutions and analytics software for healthcare facilities, ... one overall pharmacy equipment vendor in the KLAS ... leading independent healthcare research firm, compared the performance ... annual rankings. Omnicell also received the prestigious "Best ...
(Date:6/19/2013)... SAN FRANCISCO , June 19, 2013  It may ... and possible cure for breast cancer. But these were two ... Endocrine Society,s 95 th Annual Meeting & Expo that ... now some are saying this focus by some of the ... about our culture,s obsession with new research that can not ...
(Date:6/18/2013)... LAVAL, Quebec , June 18, 2013 ... and TSX: VRX) has priced its previously announced public ... Offering, the Company will issue 23,529,412 common shares at ... proceeds of approximately $2.0 billion. The Company will file ... statement on Form S-3 and will make a similar ...
Breaking Medicine Technology:Omnicell Named Top Vendor in 2013 KLAS Pharmacy Automation Equipment Rankings 2Omnicell Named Top Vendor in 2013 KLAS Pharmacy Automation Equipment Rankings 3Omnicell Named Top Vendor in 2013 KLAS Pharmacy Automation Equipment Rankings 4"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 2"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 3"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 4Valeant Pharmaceuticals Prices Public Offering Of Common Shares 2Valeant Pharmaceuticals Prices Public Offering Of Common Shares 3Valeant Pharmaceuticals Prices Public Offering Of Common Shares 4
... Calif., Dec. 27 According to the latest,science, resveratrol ... of,resveratrol plus an array of antioxidant molecules as typically ... rather than resveratrol alone. , ... The most recent study shows mega-dose resveratrol ...
... development and validation of non-animal alternative test methods , ... MatTek Corporation today announced that the ECVAM Scientific Advisory Committee ... Irritation Test (SIT) at its November meeting. ESAC concluded ... for the prediction of skin irritating and non-irritating test substances. ...
Cached Medicine Technology:Longevity Seekers Advised to Consume Modest Doses of Red Wine Molecules in Dietary Supplements (Longevinex(R)) Rather than Mega-Dose Resveratrol Alone 2Longevity Seekers Advised to Consume Modest Doses of Red Wine Molecules in Dietary Supplements (Longevinex(R)) Rather than Mega-Dose Resveratrol Alone 3EpiDerm's Skin Irritation Test Fully Validated in European Union 2
(Date:6/19/2013)... Kansas City will host its first Ciclovia event on Sept. 7, ... of Main Street in the midtown area will be restricted to ... The Main Street Corridor Development and BikeWalkKC are ... the ranks of dozens of cities across the US and Americas ... and active lifestyles. , “Ciclovia is the perfect event for the ...
(Date:6/19/2013)... Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig,s ... be classified into four distinct stages, report pathologists with ... Pennsylvania in the Annals of Neurology . This ... shows, for the first time, how the fatal degenerative ... central nervous system to other regions of brain and ...
(Date:6/19/2013)... 2013 Ultimate Medical Academy (UMA) participated ... broadcast on WFLA News Channel 8. Since its inaugural ... $84 million for All Children's Hospital in St. Petersburg, ... Years of Miracles," marked the second year UMA volunteered ... worked the phones during the Telethon, which raised a ...
(Date:6/19/2013)... 2013 “We are proud to introduce the ... like it in the U.S.,” says Shaun Johnson, Retail & ... and inexpensive solution to a very expensive problem, considering customers ... fish,” he adds. , Each package of Pond Defender ... the shape of any water garden or pond. The discs ...
(Date:6/19/2013)... the mantra of neurologists treating stroke victims has been "time ... room quickly to receive a drug that dissolves the stroke-causing ... brain tissue is saved or lost. , But ... of giving the intravenous drug known as a tissue ... ischemic (clot-caused), stroke, the most common type of stroke. ...
Breaking Medicine News(10 mins):Health News:Main Street Corridor Development Corporation and BikeWalkKC Partner to Host Main Street Day and Kansas City’s First Ciclovia 2Health News:Main Street Corridor Development Corporation and BikeWalkKC Partner to Host Main Street Day and Kansas City’s First Ciclovia 3Health News:Staging system in ALS shows potential tracks of disease progression, Penn study finds 2Health News:Ultimate Medical Academy Rallies in Support of All Children's Hospital 2Health News:Ultimate Medical Academy Rallies in Support of All Children's Hospital 3Health News:Timely treatment after stroke is crucial, UCLA researchers report 2Health News:Timely treatment after stroke is crucial, UCLA researchers report 3
... with early rheumatoid arthritis (RA) who are current smokers were ... tumor necrosis factor (TNF) inhibitors than those who never smoked. ... patients who smoked in the past did not experience a ... appear in the January 2011 issue of Arthritis & ...
... is potentially more potent, longer lasting and less ... study led by a Loyola University Health System ... a similar chemical structure to standard morphine. Dr. ... study they performed in rats "demonstrated potential clinical ...
... glaucoma tests requiring a visit to the ophthalmologist could ... by an engineer at the University of Arizona. ... sensors, specially designed microchips, and math-based programmed procedures has ... Engineering. The easy-to-use probe gently rubs the eyelid and ...
... from Virginia Mason Medical Center in Seattle, WA, have ... inappropriate medical imaging, including unnecessary computed tomography (CT) and ... in the January issue of the Journal of ... "Clinical decision support systems are point-of-order decision ...
... clinicians frequently use portable media (CDs, DVDs) to review ... magnetic resonance imaging (MRI) and computed tomography (CT) scans, ... portable media exist, according to a study in the ... College of Radiology ( www.jacr.org ). "Because ...
... DATA SHOWS OMALIZUMAB SAFE AND EFFECTIVE FOR MODERATE TO SEVERE ... New research suggests that subcutaneous omalizumab is safe and effective ... in children and adults. Researchers from Uruguay, Argentina, and Chile ... omalizumab and 1,546 received a placebo. At the end of ...
Cached Medicine News:Health News:Current smokers with early rheumatoid arthritis less responsive to TNF inhibitors, methotrexate 2Health News:Experimental drug more potent, longer lasting than morphine 2Health News:New glaucoma test allows earlier, more accurate detection 2Health News:Study finds problems with reviewing medical images from portable media 2Health News:News briefs from the January issue of Chest 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: